President and CEO, Christopher J. Burns, Ph.D., will present Venatorx Pharmaceuticals' lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium on Wednesday, March 21, 2018 at 3:15pm CT in the La Nouvelle Orleans Ballrooms A/B at the Ernest N. Morial Convention Center in New Orleans, LA.

The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”

VNRX-5133 is a new-generation BLI with unique broad-spectrum activity, covering both serine- and metallo-beta-lactamases. VenatoRx is developing VNRX-5133 in a fixed combination with the 4th generation cephalosporin, cefepime, to provide a best-in-class treatment option for infections caused by multi-drug resistant (MDR) gram-negative bacteria, including: carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa; suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens; and bioterror pathogens such as Burkholderia spp. and Salmonella spp.

This project has been funded in whole or in part with Federal funds from the National Institute for Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300019C, and Wellcome Trust under Award No. 360G-Wellcome-101999/Z/13/Z.